Clinical and Immunological Effects of p53-Targeting Vaccines

Frontiers in Cell and Developmental Biology

Ken H. Young¹  Shan Zhou²  Chunmei Fan³  Zhaoyang Zeng³  Yong Li³ 

[1] Hematopathology Division, Department of Pathology, Duke University Medical Center, Durham, NC, United States;Section of Epidemiology and Population Science, Department of Medicine, Baylor College of Medicine, Houston, TX, United States;The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medicine, Central South University, Changsha, China;

关键词: p53;    vaccine;    Cancer;    immunotherapy;    T cell;   

DOI  :  10.3389/fcell.2021.762796

来源: DOAJ

【 摘 要 】

Immunotherapy, including immune checkpoint blockade and chimeric antigen receptor T cells, is one of the most promising approaches to treat cancer. Vaccines have been effective in preventing cancers like liver cancer and cervical cancer with a viral etiology. Instead of preventing disease, therapeutic cancer vaccines mobilize the immune system to attack existing cancer. p53 is dysregulated in the majority of human cancers and is a highly promising target for cancer vaccines. Over twenty clinical trials have targeted p53 in malignant diseases using vaccines. In this work, we review the progress of vaccinations with p53 or its peptides as the antigens and summarize the clinical and immunological effects of p53-targeting vaccines from clinical trials. The delivery platforms include p53 peptides, viral vectors, and dendritic cells pulsed with short peptides or transduced by p53-encoding viruses. These studies shed light on the feasibility, safety, and clinical benefit of p53 vaccination in select groups of patients, implicating that p53-targeting vaccines warrant further investigations in experimental animals and human studies.

【 授权许可】

Unknown